NIKKEI 225
38,913.48 +296.38 (+0.77%) HANG SENG
18,880.82 -314.78 (-1.64%) CRUDE OIL
77.02 -0.55 (-0.71%) GOLD FUTURES
2,372.00 -20.90 (-0.87%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,529.66 -515.42 (-0.94%)
Johnson & Johnson (JNJ.DU)
| Previous close | 138.96 |
| Open | 139.16 |
| Bid | 141.68 x N/A |
| Ask | 142.04 x N/A |
| Day's range | 139.12 - 141.82 |
| 52-week range | 135.16 - 160.80 |
| Volume | |
| Avg. volume | 15 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
NEW BRUNSWICK, N.J., May 16, 2024--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with potential for an additional milestone payment.
- GlobeNewswire
Shockwave Medical Reports First Quarter 2024 Financial Results
SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. “The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of ou
- Business Wire
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual "Prepackaged" Reorganization
NEW BRUNSWICK, N.J., May 01, 2024--Johnson & Johnson (NYSE: JNJ) (the "Company") today announced a proposed Plan of Reorganization (the "Plan") by its subsidiary, LLT Management LLC ("LLT"), for the comprehensive and final resolution of all current and future claims related to ovarian cancer arising from cosmetic talc litigation against it and its affiliates in the United States.
